1 / 5
Laboratory Research Material
CJC-1295 NO DAC
+ Ipamorelin
10 mg per vial · Lyophilized powder
Laboratory Research Material
CJC-1295 NO DAC + Ipamorelin 10 mg per vial
$84.99
- Blend composition
-
Compound Per vial CJC-1295 NO DAC 5 mg Ipamorelin 5 mg Total per vial 10 mg - Form
- Lyophilized powder
- Packaging
- 1 × 3 mL vial, boxed
- Shipping
- FedEx 2DayShips from the U.S. Estimated arrival2 business days after dispatchWeekday dispatch · 4 p.m. ET cutoff
Delivery details
Estimated for in-stock orders using FedEx 2Day. Weekends and FedEx closures are excluded. Holiday pickups, destination and carrier delays can affect arrival. Alaska and Hawaii may take longer.
Free U.S. shipping on orders $199+
Important
Research Use Notice
All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Do not administer these products to humans or animals.
Product Documentation
Details, specifications, and documents
Description
CJC-1295 NO DAC + Ipamorelin
Buy CJC-1295 + Ipamorelin blend with NO DAC CJC-1295: 5 mg of each peptide and 10 mg total labeled material. It is supplied as lyophilized powder in one boxed 3 mL vial for laboratory research.
- CJC-1295 NO DAC: 5 mg
- Ipamorelin: 5 mg
- Total blend: 10 mg per vial
Blend or separate compounds?
A premixed vial fixes the labeled component proportions. If an experiment requires independent amounts, separate CJC-1295 NO DAC and Ipamorelin listings are available. Compare the complete formulations before treating a blend as equivalent to separately prepared materials.
The CJC component is the same standard 29-amino-acid modified GRF(1-29) used in our standalone NO DAC product, reference CAS 446036-97-1. It has no DAC attachment. Replacing it with a DAC-bearing form, or replacing Ipamorelin with GHRP-2, creates a different blend.
What the component studies show
In Raun and colleagues’ original Ipamorelin study, primary rat pituitary cells released growth hormone. Antagonist experiments distinguished a GHRP-like receptor response from the GHRH pathway. The study characterized Ipamorelin and included animal experiments; it did not test this commercial mixture.
The CJC-1295 development study examined albumin-reactive modified GRF constructs. Those persistence results are not evidence for a NO DAC blend. Studying both pathways together requires controls that separate each component’s response from the response of the mixture; synergy is not established by combining two labels.
Read the blend’s analytical records
These are labeled amounts. In the available analytical records, check which components were identified and which were quantified. One overall chromatographic purity result does not necessarily report a separate purity or amount for each peptide.
Keep component identity, formulation ratio and the report’s test methods together when matching the material to a protocol. The 3 mL capacity describes the container, not a prescribed preparation volume. Handling and stability information should apply to the complete mixture rather than being inferred from one ingredient alone.
Additional information
| CAS No. | CJC-1295 NO DAC: 446036-97-1, Ipamorelin: 170851-70-4 |
|---|---|
| Applications | Growth hormone research, muscle regeneration studies, metabolic function research |
| Purity | ≥99% |
| Synthesis | Solid-phase synthesis |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
COA & Documents
Independent lot testing
CJC-1295 NO DAC + Ipamorelin (10mg Blend) Certificate of Analysis
This product has featured batch-specific third-party laboratory documentation. The Pure Lab Peptides summary presents selected source-report fields in a consistent format; the linked original laboratory report controls if any information differs.
- Lot number
- 84704
- Report number
- IF-824-QSA-TR006-2026-127-22
- Date tested
- March 2, 2026
- Reported purity
- 99.8%
- Labeled content
- 10 mg
Product documents
Product information and laboratory resources. For lot-specific results, use the COA above.
Product & packaging information
Labeled amount, physical form and packaging for CJC-1295 NO DAC + Ipamorelin (10mg Blend).
Revision 0.4 · 2026-10-05Download PDFLaboratory handling guide
General guidance for applicable lyophilized research materials. Not a product-specific SDS.
Revision 1.0 · 2026-09-22Download PDFGeneral guides & resources
Reading a COA & Verifying Your Lot
PDF · Revision 1.0Receiving, Storage & Traceability Record
PDF · Revision 1.0Research Use & Documentation Scope
PDF · Revision 1.0Need Assistance?
Questions about product documentation?
Contact our support team for help with product records, lot information, orders or certificate verification.
